Heidelberg Pharma AG

XTRA:HPHA Voorraadrapport

Marktkapitalisatie: €121.2m

Heidelberg Pharma Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Andreas Pahl

Algemeen directeur

€450.7k

Totale compensatie

Percentage CEO-salaris53.3%
Dienstverband CEOless than a year
Eigendom CEOn/a
Management gemiddelde ambtstermijn1.7yrs
Gemiddelde ambtstermijn bestuur12.5yrs

Recente managementupdates

Recent updates

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Feb 16
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Dec 05
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Jul 21
Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Oct 16
Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Nov 28
Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

Mar 27
Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Mar 15
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Jan 17
Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Dec 14
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Analyse CEO-vergoeding

Hoe is Andreas Pahl's beloning veranderd ten opzichte van Heidelberg Pharma's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Aug 31 2024n/an/a

-€19m

May 31 2024n/an/a

-€13m

Feb 29 2024n/an/a

-€18m

Nov 30 2023€451k€240k

-€20m

Aug 31 2023n/an/a

-€22m

May 31 2023n/an/a

-€27m

Feb 28 2023n/an/a

-€19m

Nov 30 2022€328k€240k

-€20m

Aug 31 2022n/an/a

-€21m

May 31 2022n/an/a

-€22m

Feb 28 2022n/an/a

-€27m

Nov 30 2021€442k€240k

-€26m

Aug 31 2021n/an/a

-€25m

May 31 2021n/an/a

-€22m

Feb 28 2021n/an/a

-€20m

Nov 30 2020€295k€207k

-€18m

Aug 31 2020n/an/a

-€17m

May 31 2020n/an/a

-€15m

Feb 29 2020n/an/a

-€12m

Nov 30 2019€288k€200k

-€10m

Aug 31 2019n/an/a

-€10m

May 31 2019n/an/a

-€11m

Feb 28 2019n/an/a

-€12m

Nov 30 2018€286k€200k

-€12m

Aug 31 2018n/an/a

-€11m

May 31 2018n/an/a

-€11m

Feb 28 2018n/an/a

-€11m

Nov 30 2017€241k€171k

-€11m

Compensatie versus markt: De totale vergoeding ($USD 488.36K ) Andreas } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 488.36K ).

Compensatie versus inkomsten: De vergoeding van Andreas is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andreas Pahl

less than a year

Tenure

€450,663

Compensatie

Prof. Dr. Andreas Pahl is Chief Executive Officer & Spokesman of the Executive Board at Heidelberg Pharma AG since February 1, 2024 and had been its Chief Scientific Officer and Member of the Executive Man...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Andreas Pahl
CEO & Spokesman of the Executive Boardless than a year€450.66kgeen gegevens
Walter Miller
Chief Financial Officer1.5yrs€398.63kgeen gegevens
Jorg Kemkowski
Chief Operating Officer1.8yrsgeen gegevensgeen gegevens
Sylvia Wimmer
Director Corporate Communicationno datageen gegevensgeen gegevens
Andras Strassz
Chief Medical Officer3.7yrsgeen gegevensgeen gegevens
George Badescu
Chief Business Officerno datageen gegevensgeen gegevens

1.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van HPHA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Friedrich von Bohlen und Halbach
Member of the Supervisory Board19.6yrs€18.00kgeen gegevens
Georg Baur
Deputy Chairman of the Supervisory Board24.8yrs€38.00kgeen gegevens
Christof Hettich
Chairman of Supervisory Board14.5yrs€49.50kgeen gegevens
Birgit Kudlek
Member of the Supervisory Board12.5yrs€21.75kgeen gegevens
Mathias Hothum
Deputy Chairman of Supervisory Board9.3yrs€39.00kgeen gegevens
Dongzhou Liu
Member of Supervisory Board2.4yrs€21.00kgeen gegevens
Yan Xia
Member of Supervisory Board1.5yrs€9.96kgeen gegevens

12.5yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HPHA zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.5 jaar).